This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo Purchase Licensing Rights, opens new tab Companies GSK plc US FDA approves GSK's drug for liver disease-related itching | Reuters Skip to main content The company did not immediately respond to Reuters request for comment on pricing and availability details. Reporting by Sriparna Roy an ...